Cart 0

QY Research

China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2017

$3,200.00

Report Published By: QY Research
Publication Date : Feb-17
No. Of Pages: 121

Notes:
Sales, means the sales volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Revenue, means the sales value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

This report studies Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca

Market Segment by Regions (provinces), covering
South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China
Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Split by Application, this report focuses on consumption, market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in each application, can be divided into
Hospitals
Clinics
Others

Table of Contents

China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2017
1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
1.2.1 China Production Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Type in 2015
1.2.2 Preface
1.2.3 Eluxadoline
1.2.4 Alosetron
1.2.5 Rifaximin
1.2.6 Loperamide
1.2.7 Diphenoxylate + Atropine
1.2.8 Dicyclomine and Hyoscyamine
1.3 Applications of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2015
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 China Market Size (Value) of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs (2012-2022)
1.5 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Status and Outlook
1.6 Government Policies

2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity, Production and Share by Manufacturers (2015 and 2016)
2.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Share by Manufacturers (2015 and 2016)
2.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share of Top 3 and Top 5 Manufacturers

3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Profiles/Analysis
3.1 Astellas Pharmaceuticals
3.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.1.2.1 Preface
3.1.2.2 Eluxadoline
3.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.1.4 Main Business/Business Overview
3.2 Actavis
3.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.2.2.1 Preface
3.2.2.2 Eluxadoline
3.2.3 Actavis 121 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.2.4 Main Business/Business Overview
3.3 Pfizer
3.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.3.2.1 Preface
3.3.2.2 Eluxadoline
3.3.3 Pfizer 131 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.3.4 Main Business/Business Overview
3.4 GlaxoSmithKline
3.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.4.2.1 Preface
3.4.2.2 Eluxadoline
3.4.3 GlaxoSmithKline Jan Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.4.4 Main Business/Business Overview
3.5 Salix Pharmaceuticals Ltd
3.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.5.2.1 Preface
3.5.2.2 Eluxadoline
3.5.3 Salix Pharmaceuticals Ltd Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.5.4 Main Business/Business Overview
3.6 AstraZenenca
3.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification
3.6.2.1 Preface
3.6.2.2 Eluxadoline
3.6.3 AstraZenenca Million USD Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.6.4 Main Business/Business Overview

4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity, Production, Revenue, Consumption, Export and Import (2012-2017)
4.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity, Production and Growth (2012-2017)
4.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth (2012-2017)
4.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Consumption, Export and Import (2012-2017)

5 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (Value), Price Trend by Type
5.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production and Market Share by Type (2012-2017)
5.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2012-2017)
5.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2012-2017)
5.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Growth by Type (2012-2017)

6 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis by Application
6.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Market Share by Application (2012-2017)
6.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Application
6.3.2 Emerging Markets/Countries

7 ChinaIrritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis by Regions (Provinces)
7.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Production Value and Price by Regions (Provinces)(2012-2017)
7.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production and Market Share by Regions (Provinces)(2012-2017)
7.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Value and Market Share by Regions (Provinces)(2012-2017)
7.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Regions (Provinces)(2012-2017)
7.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions (Provinces)(2012-2017)
7.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Consumption, Export and Import (2012-2017)

8 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturers in 2015
9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2017-2022)
12.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity, Production, Revenue Forecast (2017-2022)
12.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Import, Export and Consumption Forecast (2017-2022)
12.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Forecast by Type (2017-2022)
12.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Application (2017-2022)
12.5 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)
12.5.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Forecast by Regions (Provinces)(2017-2022)
12.5.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Regions (Provinces)(2017-2022)
12.5.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)
12.6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast (2017-2022)

13 Research Findings and Conclusion

14 Appendix
Methodology
Analyst Introduction
Data Source


* indicates required information

* indicates required information


Share this Product


More from this collection